Intravenous combined with topical administration of tranexamic acid in primary total hip arthroplasty: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004474

Enrollment

Unknown

Registered

2014-04-05

Start date

2014-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage joint disease

Interventions

trial group:intravenous (15mg/kg) combined with topical (1000mg) use tranexamic acid

control group:intravenous (NS 100ml) combined with topical (NS 100ml) use

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: All patients undergoing primary total hip arthroplasty during study period.

Exclusion criteria

Exclusion criteria: allergy to tranexamic acid; preoperative hepatic or renal dysfunction; preoperative use of anticoagular medication seven days prior to surgery; history of fibrinolytic disorder or blood dyscrasia; cerebrovascular accident, myocardial infarction, New York heart association class III or IV heart failure, atrial fibrillation, history of deep vein thrombosis or pulmonary embolus, preoperative INR >1.4, aPTT >1.4 x normal, platelets <140000/mm3.

Design outcomes

Primary

Measure	Time frame
clincal function evaluation;drainage amount;haemoglobin level;transfusion amount;perioperative complications: deep vein thrombosis;	—

Countries

China

Contacts

Public ContactShen Bin

West China hospital, Sichuan University

shenbin_1971@163.com+86 13881878767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026